# Staccato Alprazolam and Photoparoxysmal Response

> **NCT02351115** · PHASE2 · COMPLETED · sponsor: **Nova Pneuma Inc.** · enrollment: 5 (actual)

## Conditions studied

- Epilepsy

## Interventions

- **DRUG:** A=Placebo
- **DRUG:** B=Inhaled Alprazolam 0.5 mg
- **DRUG:** C=Inhaled Alprazolam 1 m
- **DRUG:** D= Inhaled Alprazolam 2 mg
- **DRUG:** E=Placebo

## Key facts

- **NCT ID:** NCT02351115
- **Lead sponsor:** Nova Pneuma Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-01
- **Primary completion:** 2016-07
- **Final completion:** 2016-07
- **Target enrollment:** 5 (ACTUAL)
- **Last updated:** 2026-04-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02351115

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02351115, "Staccato Alprazolam and Photoparoxysmal Response". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT02351115. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*